Vaxxas Secures TGA Licence to Manufacture Therapeutic GoodsMilestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery
Vaxxas Appoints Veteran Vaccine Leader to Board as Company Advances Needle-Free Vaccine Patch Towards MarketBRISBANE, Australia and CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology company Vaxxas Pty Ltd, today announced the appointment of Mr Brent MacGregor as Independent Non-Executive Director to the Vaxxas Board. Mr MacGregor brings deep global experience in vaccine and medical device commercialisation to Vaxxas as the company advances its high-density microarray patch (HD-MAP) technology for self-administered vaccination towards market.
Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technologyBRISBANE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Vaxxas Pty Ltd, the biotechnology company pioneering the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, today announced that it has secured ~$90 million in its latest financing round.
